Clinical Trial: Study of JMKX003948 Ophthalmic Suspension in Healthy Participants

U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT06832657) titled 'Study of JMKX003948 Ophthalmic Suspension in Healthy Participants' on Dec. 25, 2024.

Brief Summary: The study is a randomized, double-blind, placebo-controlled, phase 1 study of JMKX003948 Ophthalmic Suspension to evaluate the safety, tolerability and PK of single and multiple ascending doses in healthy participants.

Participant will be randomized to receive either JMKX003948 Ophthalmic Suspension (1%, 2%, 3% or 5%) or matching placebo (JMKX003948 Ophthalmic Suspension: placebo= 6: 2, N=8 per cohort).

Five cohorts (Cohort 1-5) are planned. Cohorts could also de-escalate to a lower concentration if current formulation was not toler...